


FIG. I



F16.2B





FIG. 3A

In Vitro



In Vivo




FIG. 3B




FIG. 4A




FIG. 4B




FIG. 5A




FIG. 5B





FIG. 5C

Protein Gel

FIG.6A




³²P-Immobilized
Substrate

FIG.6B



³²P-Exogenous
Substrate

FIG.6C






FIG. 7A




FIG. 7B



FIG. 7C




FIG. 8A




FIG. 8B




FIG.9A




FIG.9B

GAATTCGGG GCGGCCAAGA CCGCGCGCGG GCGGGCCACT GCAGGGTCCG CACTGATCCG	60
CTCCGGCGGA GAGCCCGCTGC TCTGGGAAGT CAGTTCCGCT GCGGACTCCG AGGAACCGCT	120
GCGCACGAAG AGCCGTCAGT GAGTGACCCG GACTTTTCAA AGCCGGGTAG GCGCGCGAG	180
TCGACAAGTA AGAGTGGCGG AGGCATCTTA ATTAAACCCTG CGCTCCCTGG AGCAGCTGGT	240
GAGGAGGGCG CACGGGGAGG ACAGCCAGCG GGTGCGTGCG CTCTTAGAGA AACTTTCCCT	300
GTCAAAAGGCT CCGGGGGGCG CGGGTGTCCC CCGCTTGCCA CAGCCCTGTT CCGGCCCCGA	360
AACTTGTCGG CGCACGCCAA ACTAACCCTCA CGTGAAGTGA CGGACTGTTC T ATG ACT	417
	Met Thr
	1
GCA AAG ATG GAA ACC ACC TTC TAT GAC GAT GCC CTC AAC GCC TCG TTC	465
Ala Lys Met Glu Thr Thr Phe Tyr Asp Asp Ala Leu Asn Ala Ser Phe	
	5
	10
	15
CTC CCC TCC GAG AGG GGA CCT TAT GGC TAC AGT AAC CCC AAG ATC CTG	513
Leu Pro Ser Glu Arg Gly Pro Tyr Gly Tyr Ser Asn Pro Lys Ile Leu	
	20
	25
	30
AAA CAG AGC ATG ACC CTG AAC CTG GCC GAC CCA GTG GGG AGC CTG AAG	561
Lys Gln Ser Met Thr Leu Asn Leu Ala Asp Pro Val Gly Ser Leu Lys	
	35
	40
	45
	50

FIG.10A

CCG CAC CTC CGC GCC AAG AAC TCG GAC CTC CTC ACC TCG CCC GAC GTG	609
Pro His Leu Arg Ala Lys Asn Ser Asp Leu Leu Thr Ser Pro Asp Val	
55	60
65	
GGG CTG CTC AAG CTG GCG TCG CCC GAG CTG GAG CGC CTG ATA ATC CAG	657
Gly Leu Leu Lys Leu Ala Ser Pro Glu Leu Glu Arg Leu Ile Ile Gln	
70	75
80	
TCC AGC AAC GCG CAC ATC ACC ACC ACC CGC ACC CCC ACC CAG TTC CTG	705
Ser Ser Asn Gly His Ile Thr Thr Thr Pro Thr Pro Thr Gln Phe Leu	
85	90
95	
TGC CCC AAG AAC GTG ACA GAT GAG CAG GAG GCG TTC GCC GAG GCG TTC	753
Cys Pro Lys Asn Val Thr Asp Glu Gln Glu Gly Phe Ala Glu Gly Phe	
100	105
110	
GTG CGC GCC CTG GCC GAA CTG CAC ACC CAG AAC ACC CTG CCC AGC GTG	801
Val Arg Ala Leu Ala Glu Leu His Ser Gln Asn Thr Leu Pro Ser Val	
115	120
125	
130	
ACC TCG GCG GCG CAG CCG GTC AAC GCG GCA GCG ATG GTG GCT CCC GCG	849
Thr Ser Ala Ala Gln Pro Val Asn Gly Ala Gly Met Val Ala Pro Ala	
135	140
145	
GTA GCC TCG GTG GCA GCG GCG AGC GCG AGC GCG TTC ACC GCG AGC	897
Val Ala Ser Val Ala Gly Gly Ser Gly Ser Gly Gly Phe Ser Ala Ser	
150	155
160	

FIG.10B

CTG CAC AGC GAG CCG CCG GTC TAC GCA AAC CTC AGC AAC TTC AAC CCA	945
Leu His Ser Glu Pro Pro Val Tyr Ala Asn Leu Ser Asn Phe Asn Pro	
165	170
GGC GCG CTG AGC AGC GCG GCG GCG GCG GCG GCG GCG GCG GCG GCG	993
Gly Ala Leu Ser Ser Gly Gly Gly Ala Pro Ser Tyr Gly Ala Ala Gly	
180	185
CTG GCC TTT CCC GCG CAA CCC CAG CAG CAG CAG CAG CAG CCG CCG CAC CAC	1041
Leu Ala Phe Pro Ala Gln Pro Gln Gln Gln Gln Gln Gln Pro Pro His His	
195	200
CTG CCC CAG CAG ATG CCC CTG CAG CAC CCG CCG CCG CTG CAG GCC CTG AAC	1089
Leu Pro Gln Gln Met Pro Val Gln His Pro Arg Leu Gln Ala Leu Lys	
215	220
GAG GAG CCT CAG ATA GTG CCC GAG ATG CCC GCG GAG ACA CCG CCC CTG	1137
Glu Glu Pro Gln Ile Val Pro Glu Met Pro Gly Glu Thr Pro Pro Leu	
230	235
TCC CCC ATC GAC ATG GAG TCC CAG GAG GAG CCG ATC AAG GCG GAG AGG AAG	1185
Ser Pro Ile Asp Met Glu Ser Gln Glu Arg Ile Lys Ala Glu Arg Lys	
245	250
CGC ATG AGG AAC CCG ATC GCT GCC TCG AAG TGC CGA AAA AGG AAG CTG	1233
Arg Met Arg Asn Arg Ile Ala Ala Ser Lys Cys Arg Lys Arg Lys Leu	
260	265
	270

FIG.10C

GAG AGA ATC GCC CGG CTG GAG GAA AAA GTG AAA ACC TTG AAA GCT CAG	1281
Glu Arg Ile Ala Arg Leu Glu Glu Lys Val Lys Thr Leu Lys Ala Glu	
275	280
AAC TCG GAG CTG GCG TCG ACG GCC AAC ATG CTC AGG GAA CAG GTC GCA	1329
Asn Ser Glu Leu Ala Ser Thr Ala Asn Met Leu Arg Glu Glu Val Ala	
295	300
CAG CTT AAA CAC AAA GTC ATG AAC CAC GTT AAC AGT GCG TGC CAA CTC	1377
Gln Leu Lys His Lys Val Met Asn His Val Asn Ser Gly Cys Glu Leu	
310	315
ATC CTA ACG CAG CAG TTG CAA ACA TTT TGAAGAGAGA CCCTCGGGCG	1424
Ile Leu Thr Gln Glu Leu Glu Thr Phe	
325	330
CTGAGGGGCA ACGAAGAAAA AAAATAACAC AGAGAGACAG ACTTGACAAC TTGACAACTT	1484
CGGACGGAGA GAAAAAAGAA GTGTCCGAGA ACTAAAGCCA AGGTATCCA AGTTGACTG	1544
GGTTCGGTCT GACGGCCCC CCAGTGTGCA CGAGTGGGAA CCACCTGGTC CCGCCCTCCC	1604
TTGGCGTGA GCCAGGAGC GCGCCGCTGG GGGCTGCCCC GCTTTGGGGA CCGGCTGTCC	1664
CCCCCGGAAC GGAACGTTGG ACTTTCGTTA ACAATTGACCA AGAACTGCAT GGACCTAACA	1724

FIG.10D

TTCGATCTCA	TTCAGTATTA	AAGCGCGCAG	GGGAGCGGG	TTACAACCTG	CAATAGAGAC	1784
TGTAAGATTGC	TTCTGTAGTA	CTCCTTAAGA	ACACAAGCG	GGGGAGGGT	TGGGAGCGG	1844
CGGCAGGAGC	GAGGTTTGTG	AGAGCGAGGC	TGAGCCTACA	GATGAAGCTCT	TTCTGGCCTG	1904
CTTTCCTTAA	CTGTGTATGT	ACATATATAT	ATTTTTTAAT	TTGATTAAAG	CTGATTACTG	1964
TCAATAAACA	GCTTCATGCC	TTTGTAACTT	ATTCTTGTG	TGTTGTGTTG	GGATCCTGCC	2024
CAGTGTGTT	TGTAATAAAG	AGATTGCGAG	CAGTCTGAGT	TTACCAATTG	TAATAAAGTA	2084
TATAATTTT	TT					2096

FIG.10E




FIG.11A




FIG.11B




FIG. 11C

FIG. 12A





FIG. 12B






FIG.12C




FIG.13A




FIG.13B

FIG.13C

FR3T3

· T A T/A T/A

PC12

· T A T/A T/A



CV-1

· T T T/A T/A

Thymus

· T A T/A T/A



FIG.14

FIG.15A




FIG.15C




FIG.15B




FIG.15D



FIG.16A

CsA	+	-	-	-	-
anti-CD28	+	+	-	+	-
anti-CD3	+	+	+	-	-



FIG.16B

CsA	-	-	-	-	+
anti-CD28	-	-	+	+	+
anti-CD3	-	+	-	+	+





FIG.16C

	1	2	3	4	5	6	7	8	9	10	11
CsA	-	-	-	-	-	-	+	-	+	-	+
anti-CD28	-	-	-	-	+	-	-	-	-	+	+
anti-CD3	-	-	-	+	-	-	-	+	+	-	-
A	-	-	+	-	-	+	+	-	-	-	-
T	-	+	-	-	-	+	+	+	+	+	+






FIG. 17A




FIG. 17B